MAINTENANCE THERAPY OF REMISSION IN PATIENTS WITH MULTIPLE MYELOMA
https://doi.org/10.51523/2708-6011.2011-8-2s-9
Abstract
High-dose chemotherapy (HDC) followed by autologous hematopoietic stem cell transplantation (auto-HSCT) can achieve remission in 90 % patients with multiple myeloma. Unfortunately, the duration of this remission is less than 3 years. The development of the methods to maintain the remission and to control minimal residual disease in patients with multiple myeloma is a pressing task for hematologists. In the group of the patients treated with α-interferon, after HDC with autologous HSCT the dual response rate was significantly higher (p < 0,05) and relapse rates were significantly lower (p < 0,05) in comparison with the group of patients treated that α-interferon.
Keywords
множественная миелома,
двойная аутологичная трансплантация гемопоэтических стволовых клеток крови,
высокодозная химиотерапия,
терапия поддержания ремиссии,
минимальная остаточная болезнь,
multiple myeloma,
a double autologous transplantation of hematopoietic stem cell,
high-dose chemotherapy,
therapy to maintain remission,
minimal residual disease
About the Authors
I. A. Iskrov
Republican Research Center for Radiation Medicine and Human Ecology
Belarus
Belarus
A. L. Uss
Republican Research Center for Radiation Medicine and Human Ecology
Belarus
Belarus
V. V. Smolnikova
Municipal Clinical Hospital № 9
Belarus
Belarus
D. G. Tsvirko
Republican Research Center for Pediatric Oncology and Hematology
Belarus
Belarus
V. A. Zmachinsky
Belarusian Medical Academy of Postgraduate Education
Belarus
Belarus
References
1. Андреева, Н. Е. Множественная миелома: прошлое, настоящее, будущее / Н. Е. Андреева // Гематология и трансфузиология. - 1998. - № 3. - С. 4-10.
2. Алкеран, лейкеран, милеран, 6-меркаптопурин, тиогуанин, веллферон, зовиракс в онкологической практике / М. А. Волкова [и др.]; под ред. М. А. Волковой. - М.: Полигран, 1994. - 96 с.
3. Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United Kingdom Medical Research Council Trials between 1980 and 2002 / B. M. Augustson [et al.] // J. Clin. Oncol. - 2005. - Vol. 23. - P. 9219-9226.
4. MacLennan, I. C. Objective evaluation of the role of vincristine in induction and maintenance therapy for myelomatosis. Medical Research Council Working Party on Leukaemia in Adults / I. C. MacLennan, J. Cusick, Br. J. Cancer. - 1985. - Vol. 52, № 2. - P. 153-158.
Review
For citations:
Iskrov I.A., Uss A.L., Smolnikova V.V., Tsvirko D.G., Zmachinsky V.A. MAINTENANCE THERAPY OF REMISSION IN PATIENTS WITH MULTIPLE MYELOMA. Health and Ecology Issues. 2011;(2S):33-36. (In Russ.) https://doi.org/10.51523/2708-6011.2011-8-2s-9
Views: 262
Email this article 